Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Novel coronavirus pneumonia vaccine based on novel adenovirus vector sad23l and/or ad49l

A technology of ad49l-ncov-s and adenovirus, applied in virus/bacteriophage, microbe-based methods, viruses, etc., can solve problems such as limiting the application of adenovirus vectors

Active Publication Date: 2021-06-29
广州佰芮慷生物科技有限公司
View PDF30 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the pre-existing high level of immune response against common human adenoviruses (Ad5 or Ad2) in the population limits the application of adenoviral vectors.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel coronavirus pneumonia vaccine based on novel adenovirus vector sad23l and/or ad49l
  • Novel coronavirus pneumonia vaccine based on novel adenovirus vector sad23l and/or ad49l
  • Novel coronavirus pneumonia vaccine based on novel adenovirus vector sad23l and/or ad49l

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0050] Example 1 Preparation of novel coronavirus vaccines based on replicated defective adenoviral carriers SAD23L and AD49L

[0051] 1. Codon optimization and acquisition of exogenous gene s.

[0052] SARS-COV-2 petrochemical protein (S) gene sequence derived from a new coronavirus strain (GenBank No. Mn908947.3), using software UpGene to optimize the optimization of the codon, so that the exogenous gene is more suitable for mammals The cells were expressed, and the gene sequence after the optimization of SEQ ID NO: 1 was found to obtain a plasmid PMV-NCOV-S obtained by obtaining an optimized exogenous gene sequence in China.

[0053] 2. Recombinant adenoviral vector construction and virus packaging.

[0054] 2.1 Construction of shuttle plasmid pSHUTTLE2-CMV-S

[0055] Use the plasmid PMV-NCOV-S containing the gene sequence S of the whole gene EcoRi with Bamhi Differentiated, recovered enzyme digestion, and the product was ligated to the gluner PSHUTTLE2-CMV-FLAG for connection,...

Embodiment 2

[0073] Example 2 Immunization Evaluation of COVID-19 Vaccine SAD23L-NCOV-S in Mouse Model

[0074] 1. Recombinant adenovirus vaccine SAD23L-NCOV-S induced evaluation of specific body fluid immunity

[0075] 1.1 vaccination titer and site vaccination

[0076] The 5 weeks of SPF-class female C57BL / 6 mice were purchased from the South Medical University Animal Center, which was raised in the Southern Hospital Animal Center. All animal feeding and experiments are in line with national and institutional provisions on animal benefits. The injection volume is 100 μl, and the blood is taken from the blood, and the serum determination binding antibody and neutralizing antibody levels were isolated after immunization. The group of mice, as shown in Table 1:

[0077] Table 1: SAD23L-NCOV-S immunized mice packet, immunot dose and inoculation site

[0078]

[0079] 1.2 Vaccine immunization mice induced specificity for the binding antibody levels of s proteins and RBD proteins

[0080]After...

Embodiment 3

[0100] Example 3 Immunization Evaluation of COVID-19 Vaccine Pneumonia COVID-19 Vaccine AD49L-NCOV-S in Mouse Model

[0101] 1. Recombinant adenovirus vaccine AD49L-NCOV-S induced evaluation of specific body fluid immunity

[0102] 1.1 vaccination titer and site vaccination

[0103] The 5 weeks of SPF-class female C57BL / 6 mice were purchased from the South Medical University Animal Center, which was raised in the Southern Hospital Animal Center. All animal feeding and experiments are in line with national and institutional provisions on animal benefits. The injection volume is 100 μl, and the blood is taken from the blood, and the serum determination binding antibody and neutralizing antibody levels were isolated after immunization. The group of mice, the immunization is shown in Table 2:

[0104] Table 2: AD49L-NCOV-S immunized mice group, immunot dose and inoculation site

[0105]

[0106] 1.2 Vaccine immunization mice induced specificity for the binding antibody levels of s...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
Login to View More

Abstract

The invention discloses a novel coronavirus pneumonia COVID-19 vaccine based on novel adenovirus vector Sad23L and / or Ad49L. By optimizing the exogenous gene, the expression of the exogenous protein can be significantly improved, and at the same time further try to use the rare human or monkey adenovirus as the carrier to avoid the pre-existing immune response against the common adenovirus. The 19 vaccine can induce high levels of humoral and cellular immunity in animals, and no side effects were found after animal immunization. The novel coronavirus pneumonia COVID-19 vaccine of the present invention is safe and effective and can be prepared rapidly and in large quantities, so it is a candidate vaccine strain that can be used to prevent SARS-CoV-2 infection.

Description

Technical field [0001] The invention belongs to the biotechnology field, and more particularly to a new type of coronavirus pneumonia-19 vaccine based on new adenoviral carriers SAD23L and / or AD49L. Background technique [0002] 2019 coronary virus disease (COVID-19) pathogens is identified as a new coronavirus (Severe Acuterespiratory Syndrome Coronavirus 2, SARS-COV-2) is a similar diamond acute respiratory syndrome (SARS-COV, about 79%) And the Novel coronavirus of ß coronavirus, Sarbecovirus subordinates of the Middle East respiratory syndrome. SARS-COV-2 people - human communication ability is stronger than SARS-COV and MERS-COV, but their pathogen is lower than SARS-COV, and there is a mild or no obvious clinical symptom infection. Given the existence of occultivial poison, it can be speculated that in the state of first-level response, even if the epidemic has been effectively controlled, the SARS-COV-2 carrying the infected person may show continuous distribution, time ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12N15/50C07K14/165C12N15/861C12N7/01A61K39/215A61P31/14C12R1/93
CPCA61K39/12A61P31/14C07K14/005C12N7/00C12N15/86C12N2710/10321C12N2710/10343C12N2710/10351C12N2770/20022C12N2770/20034
Inventor 罗升学刘博超张攀丽
Owner 广州佰芮慷生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com